文献速递甲状腺疾病糖尿病肥胖与代谢综合征

GLP-1受体激动剂暴露与分化型甲状腺癌结构进展风险

Exposure to GLP-1RA and Risk of Structural Progression in Differentiated Thyroid Cancer.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

这项回顾性队列研究在纽约三级中心纳入536例暴露于GLP-1RA的分化型甲状腺癌(DTC)患者,按年龄、诊断日期、TNM分期、BMI和糖尿病1:1匹配536例未暴露患者。结论认为不应因DTC而拒绝有适应证的GLP-1RA心代谢获益。

要点

  • GLP-1RA暴露与DTC复发/进展风险无显著关联。
  • 匹配后两队列各536例,中位随访69个月。
  • 有适应证DTC患者不应被拒绝GLP-1RA心代谢获益。

核心结论

  • 未发现GLP-1RA与DTC复发/进展显著相关。
  • 有临床指征的DTC患者不应被拒绝GLP-1RA的心代谢获益。

研究设计与样本

  • 纽约三级中心回顾性观察性队列研究。
  • 536例暴露于GLP-1RA的DTC患者按年龄、诊断日期、TNM分期、BMI和糖尿病1:1匹配536例未暴露患者。
  • 采用多状态模型将GLP-1RA作为时间依赖变量评估从无/稳定疾病向复发/进展的转变。

主要发现

  • 共1072例患者,中位年龄49岁,71%女性,54%糖尿病,平均BMI±SD 35±7 kg/m²。
  • 84%为AJCC I期,58%为ATA中或高复发风险,GLP-1RA中位暴露16个月,中位随访69个月。

临床怎么用

  • 对符合适应证的DTC患者,GLP-1RA的心代谢获益不应因甲状腺癌病史而被拒绝。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) benefit patients with diabetes mellitus (DM) and obesity. While contraindicated in medullary thyroid cancer, their effect in well-differentiated thyroid cancer (DTC) remains poorly understood. OBJECTIVE: To determine the impact of GLP-1RAs on the risk of DTC recurrence/progression. DESIGN AND SETTING: Retrospective observational cohort study at a tertiary care center in New York. PARTICIPANTS, INTERVENTION, AND MAIN OUTCOME: Five hundred thirty-six patients with DTC exposed to GLP-1RA were matched 1:1 to 536 patients with DTC never exposed to GLP-1RA by age, date of DTC diagnosis, TNM stage, body mass index (BMI), and DM. A multistate model enabled us to assess the impact of GLP-1RA as a time-dependent variable on the transition of patients with DTC from a "no/stable disease" state to a "recurrence/progression" state. RESULTS: A total of 1072 patients, median age 49, 71% females, 54% with DM, mean BMI ± SD 35 ± 7 kg/m², 84% with American Joint Committee on Cancer stage I disease, 58% with American Thyroid Association (ATA) intermediate or high risk of recurrence, with median GLP-1RA exposure of 16 months were followed for a median of 69 months. GLP-1RA use was not significantly associated with recurrence or progression of disease in the survival cohort [hazard ratio (HR) = 0.87, 95% confidence interval (CI) 0.62-1.21, P = .39) or the entire cohort (HR = 0.75, 95% CI 0.54-1.03, P = .07) on a multivariable model adjusted for age, ATA risk, radioactive iodine therapy, and DM. CONCLUSION: We did not find GLP-1RA to be significantly associated with recurrent/progressive DTC. Eligible patients with DTC should not be denied the cardiometabolic benefits of GLP-1RA when clinically indicated.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Patrizio A, Mauguen A, Fagin JA, et al. Exposure to GLP-1RA and Risk of Structural Progression in Differentiated Thyroid Cancer. J Clin Endocrinol Metab. 2026. PMID: 41693146. doi:10.1210/clinem/dgag051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。